• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.

作者信息

Van den Bogaert W, van der Schueren E, Horiot J C, De Vilhena M, Schraub S, Svoboda V, Arcangeli G, de Pauw M, van Glabbeke M

机构信息

Radiotherapy Department, University Hospital, Gasthuisberg, Leuven, Belgium.

出版信息

Radiother Oncol. 1995 May;35(2):100-6. doi: 10.1016/0167-8140(95)01539-s.

DOI:10.1016/0167-8140(95)01539-s
PMID:7569017
Abstract

In trial no. 22811 on a randomized comparison of multiple fractions per day (MFD), with or without misonidazole, to conventional fractionation in advanced head and neck cancer, a large number (523) of patients was entered in a short period of time. No differences in treatment results were obtained, but the study created an important database, allowing for detailed evaluation of the most important factors influencing prognosis. In univariate analysis, factors significantly influencing survival and locoregional control were: performance status, histological differentiation, tumor site, tumor and nodal staging, and tumoral and nodal volume. In multivariate analysis, significant factors for survival were nodal involvement, tumor stage, performance status, and tumor site. Significant factors for locoregional control were nodal involvement and total tumor burden. This analysis suggests that total tumor burden (volume) should be included in the interpretation of treatment results in head and neck cancer.

摘要

相似文献

1
The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.
Radiother Oncol. 1995 May;35(2):100-6. doi: 10.1016/0167-8140(95)01539-s.
2
Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer.
Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):587-91. doi: 10.1016/0360-3016(86)90067-2.
3
The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
Radiother Oncol. 1995 May;35(2):91-9. doi: 10.1016/0167-8140(95)01538-r.
4
Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group.
Radiother Oncol. 1985 Feb;3(2):139-44. doi: 10.1016/s0167-8140(85)80018-9.
5
Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.米索硝唑增敏放疗对头颈部 III-IV 期鳞状细胞癌患者的预后无显著影响。
Int J Radiat Oncol Biol Phys. 1987 Aug;13(8):1155-60. doi: 10.1016/0360-3016(87)90188-x.
6
Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer.米索硝唑与高压氧照射:晚期头颈癌随机试验的最终报告
Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1343-6. doi: 10.1016/0360-3016(86)90168-9.
7
Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial.顺铂与放疗同步进行传统及改良分割方案治疗局部晚期头颈癌:一项欧洲癌症研究与治疗组织(EORTC)的随机II期试验
Eur J Cancer. 2002 Mar;38(5):667-73. doi: 10.1016/s0959-8049(01)00425-7.
8
The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of Cancer).
Int J Radiat Oncol Biol Phys. 1982 Oct;8(10):1649-55. doi: 10.1016/0360-3016(82)90282-6.
9
Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck.伴有或不伴有米索硝唑的超分割放疗:头颈部 III-IV 期鳞状细胞癌前瞻性随机研究结果
Int J Radiat Oncol Biol Phys. 1984 Oct;10(10):1845-9. doi: 10.1016/0360-3016(84)90260-8.
10
Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.贫血与局部晚期头颈癌患者生存率降低及局部区域复发增加相关:RTOG 85-27的二次分析
Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1069-75. doi: 10.1016/s0360-3016(98)00348-4.

引用本文的文献

1
Role of primary tumor volume and metastatic lymph node volume in response to curative effect of definitive radiotherapy for locally advanced head and neck cancer.原发肿瘤体积和转移淋巴结体积在局部晚期头颈癌根治性放疗疗效中的作用。
Eur J Med Res. 2024 Feb 4;29(1):98. doi: 10.1186/s40001-024-01691-0.
2
Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects.口咽癌的剂量递增:长期随访及副作用
Cancers (Basel). 2023 Apr 30;15(9):2580. doi: 10.3390/cancers15092580.
3
Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy.
放疗治疗 p16 阳性和 p16 阴性口咽鳞癌患者的原发肿瘤体积与预后。
Radiat Oncol. 2022 Jun 14;17(1):107. doi: 10.1186/s13014-022-02074-7.
4
Trimodal therapy in T2-4aN0M0 bladder cancer--How to select the best candidate?T2-4aN0M0 期膀胱癌的三联疗法——如何选择最佳患者?
Cancer Med. 2020 Nov;9(22):8491-8497. doi: 10.1002/cam4.3478. Epub 2020 Sep 22.
5
Tumor Volumes and Prognosis in Laryngeal Cancer.喉癌的肿瘤体积与预后
Cancers (Basel). 2015 Nov 10;7(4):2236-61. doi: 10.3390/cancers7040888.
6
Intraobserver variability in the MR determination of tumor volume in squamous cell carcinoma of the pharynx.咽鳞状细胞癌肿瘤体积的磁共振成像测量中观察者内变异性
AJNR Am J Neuroradiol. 2004 Jun-Jul;25(6):1092-8.